Los Angeles, California, USA, April 14th, 2023 – ImaginAb Inc., a global biotechnology company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPETTM) imaging agent and radiopharmaceutical therapies (RPT) announces a poster presentation at AACR 2023 (# 3577 / 2 Poster PET, MRI, and CT Imaging April 18, 2023) of an independent analysis undertaken by AstraZeneca (LSE/STO/Nasdaq: AZN), on data from ImaginAb’s IAB-CD8-201 ‘iCorrelate’ Phase II study. The analysis shows baseline and early on-treatment CD8 ImmunoPET/CT may be able to distinguish responders from non-responders in patients receiving standard of care immune checkpoint blockade (ICB) therapy. The poster analysis notes:
Ian Wilson, Chief Executive Officer of ImaginAb, said:
“These results of the independent data analysis highlight the potential for CD8 ImmunoPET/CT to be used as a robust decision maker in investigational immunotherapy trials for early assessment of pharmacodynamic response, which may help establish drug mechanism of action, prioritization of indications/tumor types, dose optimization and escalation, and to evaluate efficacy of mono vs combination therapies.”
A first assessment of CD8-PET/CT with 89-Zr-Crefmirlimab as predictive biomarker for response to standard of care immunotherapy in patients with solid tumors.
Abstract # 3577/2 /Poster
PET, MRI, and CT Imaging
18 April 2023
A clinical stage, revenue-generating global biotechnology company developing next-generation imaging agents and radiopharmaceutical therapy products through its proprietary minibody and cys-diabody platforms. The lead candidate, CD8 ImmunoPET™, is currently in Phase II clinical trials and has been licensed by pharmaceutical and biotech companies for use in immunotherapy clinical trials.
About CD8 ImmunoPET™
An 89Zr-labelled minibody designed to bind to the CD8 receptor on human T cells for quantitative, non-invasive PET imaging. This method is currently being researched to determine whether it may be used to diagnose the immune status of a patient, to measure the efficacy of immunotherapies and predict patient outcomes.
Contact info: firstname.lastname@example.org
More information: https://imaginab.com/products/...